BB Biotech AG
BB Biotech AG (BBAGF) Financial Performance & Income Statement Overview
Analyze BB Biotech AG (BBAGF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
BB Biotech AG (BBAGF) Income Statement & Financial Overview
View the income breakdown for BB Biotech AG BBAGF across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $108000.00 | $67.14M | -$149.69M | -$79.33M |
| Cost of Revenue | $0.00 | $0.00 | -$1.24M | -$79.36M |
| Gross Profit | $108000.00 | $67.14M | -$148.45M | $32000.00 |
| Gross Profit Ratio | $1.00 | $1.00 | $0.99 | -$0.00 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $6.08M | $6.43M | $7.46M | $7.73M |
| Operating Expenses | $6.08M | $6.43M | $6.57M | $7.73M |
| Total Costs & Expenses | $6.08M | $6.43M | $7.46M | $7.73M |
| Interest Income | $0.00 | $0.00 | $0.00 | $32000.00 |
| Interest Expense | $0.00 | $0.00 | $1.20M | $1.57M |
| Depreciation & Amortization | $6.07M | -$59.78M | $0.00 | $7.70M |
| EBITDA | $0.00 | $0.00 | $0.00 | -$78.73M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.99 |
| Operating Income | -$5.97M | $60.70M | -$157.15M | -$87.06M |
| Operating Income Ratio | -$55.26 | $0.90 | $1.05 | $1.10 |
| Other Income/Expenses (Net) | -$234.95M | -$1.05M | -$150.58M | -$79.36M |
| Income Before Tax | -$240.92M | $59.65M | -$157.15M | -$87.06M |
| Income Before Tax Ratio | -$2230.73 | $0.89 | $1.05 | $1.10 |
| Income Tax Expense | $15000.00 | $3000.00 | $19000.00 | $19000.00 |
| Net Income | -$240.93M | $59.66M | -$157.17M | -$87.08M |
| Net Income Ratio | -$2230.87 | $0.89 | $1.05 | $1.10 |
| EPS | -$4.40 | $1.08 | -$2.87 | -$1.60 |
| Diluted EPS | -$4.40 | $1.09 | -$2.87 | -$1.60 |
| Weighted Avg Shares Outstanding | $54.74M | $55.21M | $54.76M | $54.43M |
| Weighted Avg Shares Outstanding (Diluted) | $54.74M | $54.80M | $54.76M | $54.43M |
Financial performance has remained strong, with revenue growing from -$79.33M in Q2 2024 to $108000.00 in Q1 2025. Gross profit continued to perform well, with margins at 100% in the latest quarter. Operating income reached -$5.97M in Q1 2025, holding a steady -5526% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $0.00. Net income dropped to -$240.93M, keeping EPS at -$4.40. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan